Sun gets favourable US supreme court verdict
19 April 2012 5:46 PM GMT
Sun Pharmaceutical Industries on Wednesday said the US Supreme Court has given a favourable verdict in its patent case against Novo Nordisk over generic Prandin tablets used for treating diabetes.
US Supreme Court has ruled in favour of the company's subsidiary, Caraco Pharmaceutical Laboratories, in it's patent litigation against Novo Nordisk over Caraco's generic version of prandin, repaglinide tablets, Sun Pharma said in a statement.
‘The Supreme Court, in a unanimous opinion, concluded that Caraco can seek correction of Novo Nordisk's inaccurate use code regarding the combination use of repaglinide and metformin for the treatment of type II diabetes,’ it added.
Prandin is a registered trademark of Denmark-based drug firm Novo Nordisk.
US Supreme Court has ruled in favour of the company's subsidiary, Caraco Pharmaceutical Laboratories, in it's patent litigation against Novo Nordisk over Caraco's generic version of prandin, repaglinide tablets, Sun Pharma said in a statement.
‘The Supreme Court, in a unanimous opinion, concluded that Caraco can seek correction of Novo Nordisk's inaccurate use code regarding the combination use of repaglinide and metformin for the treatment of type II diabetes,’ it added.
Prandin is a registered trademark of Denmark-based drug firm Novo Nordisk.
Next Story
